0000914475-24-000092.txt : 20240315 0000914475-24-000092.hdr.sgml : 20240315 20240315171938 ACCESSION NUMBER: 0000914475-24-000092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240313 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: POPS RICHARD F CENTRAL INDEX KEY: 0001126490 ORGANIZATION NAME: STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24756028 MAIL ADDRESS: STREET 1: 10555 SCIENCE CENTER DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1710537566.xml FORM 4 X0508 4 2024-03-13 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001126490 POPS RICHARD F 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 0 0 0 1 Common Stock 2024-03-13 4 M 0 23200 42.76 A 52712 D Common Stock 2024-03-13 4 S 0 23200 140.3285 D 29512 D Non-Qualified Stock Option 42.76 2024-03-13 4 M 0 23200 42.76 D 2025-05-28 Common Stock 23200 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025. /s/ Darin Lippoldt, Attorney-in-Fact 2024-03-15